Trial reportClinical oral investigations2025
Efficacy of a 1% ibuprofen nanostructured topical gel in reducing in-office bleaching sensitivity following 35% hydrogen peroxide application: a randomized, controlled, triple-blind, split-mouth clinical trial.
Trial report in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aimed to evaluate the efficacy of a 1% ibuprofen nanostructured topical gel in controlling in-office bleaching sensitivity (BS) and its impact on tooth color change.
methodsA randomized, controlled, triple-blind, split-mouth clinical trial was conducted with 40 participants. The nanostructured ibuprofen gel (I) and placebo (P) were applied for 10 min before and after bleaching (35% hydrogen peroxide; 1 × 50 min; two sessions, one week apart) on each hemi-arch, randomly assigned. Bleaching sensitivity (BS) was assessed using the Visual Analog Scale (VAS), calculating absolute risk, relative risk, and BS intensity. The color change was measured subjectively with the Vitapan Classical
resultsNo statistically significant differences were found between I and P for absolute risk of BS (80% vs. 77%) or BS intensity at 1 h (0.6 vs. 0.8), 24 h (0.2 vs. 0.1), or 48 h (0.0 vs. 0.0). BS intensity was low to moderate. The color change was also statistically similar between groups: ΔE (12.81 ± 4.68 vs. 12.65 ± 5.32), ΔE00 (8.50 ± 3.71 vs. 8.52 ± 4.03), ΔWID (8.06 ± 7.55 vs. 8.34 ± 6.90), and ΔSGU (7.42 ± 2.94 for both).
conclusionThe novel 1% ibuprofen nanostructured topical gel was ineffective in reducing BS and did not affect tooth color change. CLINICAL RELEVANCE: The 1% ibuprofen nanostructured topical gel did not interfere with tooth color change but was ineffective in reducing the risk or intensity of in-office bleaching sensitivity. Although the formulation yielded positive results in a previous animal study, these outcomes were not replicated in humans, underscoring the need for clinical trials to confirm the efficacy of any approach for managing bleaching sensitivity, even if successful in animal models. CLINICAL TRIAL REGISTRATION NUMBER: RBR-4ng46xj.
Indexed as
Identifiers
40407907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.